Ultragenyx Pharmaceutical Q4 EPS $(1.52) Beats $(1.62) Estimate, Sales $127.39M Beat $119.38M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported Q4 earnings with losses of $(1.52) per share, surpassing the $(1.62) estimate, and sales of $127.39M, exceeding the $119.38M estimate. This represents a significant improvement over the previous year.
February 15, 2024 | 9:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ultragenyx Pharmaceutical reported better-than-expected Q4 earnings and sales, indicating a strong performance and improvement over the previous year.
Beating both EPS and sales estimates suggests operational efficiency and growth, likely leading to positive investor sentiment and potential stock price appreciation in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100